lupkynis
otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresantai - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).
ximluci
stada arzneimittel ag - ranibizumabas - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologai - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumabas - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologai - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
herwenda
sandoz gmbh - trastuzumabas - breast neoplasms; stomach neoplasms - antinavikiniai vaistai - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologai - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.
ofost
as grindeks - oksitocinas - injekcinis ar infuzinis tirpalas - 5 tv/ml - oxytocin
ofost
as grindeks - oksitocinas - injekcinis ar infuzinis tirpalas - 10 tv/ml - oxytocin
bupivacaine accord
accord healthcare b.v. - bupivakainas - injekcinis tirpalas - 2,5 mg/ml; 5 mg/ml - bupivacaine
ipidacrine hydrochloride grindeks
as grindeks - ipidakrino hidrochloridas - injekcinis tirpalas - 5 mg/ml - anticholinesterases
ipidacrine hydrochloride grindeks
as grindeks - ipidakrino hidrochloridas - injekcinis tirpalas - 15 mg/ml - anticholinesterases